Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Angiotensin II ¼ö¿ëü ±æÇ×Á¦ Åõ¿©°¡ Cyclosporine ½Åµ¶¼º¿¡ ÀÇÇÑ ¿°Áõ¹ÝÀÀ¿¡ ¹ÌÄ¡´Â ¿µÇâ The anti-inflammatory effects of angiotensin II blockade in animal model of cyclosporine-induced nephropathy

´ëÇѳ»°úÇÐȸÁö 2004³â 67±Ç 6È£ p.615 ~ 624
¼ÛÁØâ, ±è¿ë¼ö, ¾çö¿ì, ÀåÀ±½Ä, ¹æº´±â, ½Å¹ÌÁ¤, ¿ì¼º¿ë, À±ÇýÀº, Àü¿¬ÁÖ, Çüº¹Áø, ¿ìÇö¿µ, ÃÖ¹ü¼ø,
¼Ò¼Ó »ó¼¼Á¤º¸
¼ÛÁØâ ( Song Joon-Chang ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

±è¿ë¼ö ( Kim Yong-Soo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¾çö¿ì ( Yang Chul-Woo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀåÀ±½Ä ( Chang Yoon-Sik ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹æº´±â ( Bang Byung-Kee ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Å¹ÌÁ¤ ( Shin Mi-Jung ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿ì¼º¿ë ( Woo Seong-Yong ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
À±ÇýÀº ( Yoon Hye-Eun ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Àü¿¬ÁÖ ( Chun Yeon-Joo ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Çüº¹Áø ( Hyoung Bok-Jin ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¿ìÇö¿µ ( Woo Hyun-Young ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÃÖ¹ü¼ø ( Choi Bum-Soon ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç

Abstract

¸ñÀû: ½ÅÀå À̽Ľà Åõ¿©µÇ´Â cyclosporine (CsA)Àº ¿ì¼öÇÑ ¸é¿ª ¾ïÁ¦Á¦ÀÌÁö¸¸ Àå±â°£ Åõ¿©·Î ¼¼´¢°ü °£Áú¼¶À¯È­¿Í ¿°Áõ¹ÝÀÀÀ» À¯¹ßÇÑ´Ù. ¸¸¼º CsA ½Åµ¶¼º º´Å»ý¸®´Â ´Ù¾çÇÏ°Ô Á¦½ÃµÇ°í ÀÖÀ¸¸ç ÀÌÁß ·¹´Ñ-¾ÈÁö¿ÀÅٽŰèÀÇ È°¼ºÈ­°¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î º¸°í µÇ°íÀÖ´Ù. ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â ¾ÈÁö¿ÀÅٽŠ¥± ¼ö¿ëü ±æÇ×Á¦ÀÎ losartan (LSRT) Åõ¿©°¡ CsA¿¡ ÀÇÇÑ ½ÅÀå³» ¿°Áõ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ´ÂÁö ¼¼´¢°ü °£Áú ¼¶À¯È­¿Í ´ë½Ä¼¼Æ÷ ħÀ±ÀÇ ÁöÇ¥ÀÎ ED-1, ¿°Áõ¹ÝÀÀÀÇ ÁöÇ¥ÀÎ C-reactive protein(CRP), osteopontin (OPN) mRNA ¹ßÇöÀ» ÅëÇØ ¿¬±¸ÇÏ¿´´Ù.

´ë»ó ¹× ¹æ¹ý: ¸ö¹«°Ô 225 g¿¡¼­ 250 g±îÁö ³ª°¡´Â ¼öÄÆ ÈòÁã¿¡ 0.05% ³ªÆ®·ýÀÇ Àú¿°½ÄÀ̸¦ 1ÁÖÀÏ°£ Åõ¿©ÇÑ µÚ 4°³ÀÇ ±ºÀ¸·Î ³ª´©¾î ½ÇÇèÀ» ½Ç½ÃÇß´Ù. ´ëÁ¶±º(Vehicle, VH)Àº ¿Ã¸®ºêÀ¯¸¦ ¸ÅÀÏ 1 mg/kg·Î 4ÁÖ°£ ÇÇÇÏ·Î ÁÖ»çÇÏ¿´´Ù. CsA±ºÀº CsA¸¦ 15 mg/kg·Î ¸ÅÀÏ 4ÁÖ°£ ÇÇÇÏÁÖ»ç ÇÏ¿´´Ù. ±×¸®°í LSRT´Â 100 mg/L¸¦ °æ±¸·Î VH±º°ú CsA±º¿¡ °¢°¢ º´ÇÕÅõ¿© ÇÏ¿´´Ù. ¸¸¼ºCsA ½Åµ¶¼º ¹ß»ý À¯¹«´Â ½Å±â´É°ú ½ÅÁ¶Á÷ÀÇ ¼¶À¯È­ Á¤µµ·Î È®ÀÎÇÏ¿´´Ù. LSRTÀÇ Ç׿°Áõ È¿°ú´Â ½ÅÀå Á¶Á÷³»CRP ¾ç¼º ¼¼Æ÷¼ö, OPN mRNA ¹× ´Ü¹é ¹ßÇöÁ¤µµ, ED-1¿¡ ¾ç¼ºÀÎ ´ë½Ä¼¼Æ÷ ħÀ±Á¤µµ·Î ÃøÁ¤ÇÏ¿´´Ù.

°á°ú:
1. CsA±º¿¡¼­´Â VH±º¿¡ ºñÇØ ½Å±â´ÉÀÌ °¨¼Ò(Ç÷Áß Å©·¹¾ÆƼ´ÑÀÇ Áõ°¡¿Í Å©·¹¾ÆƼ´Ñ Á¦°ÅÀ²ÀÇ °¨¼Ò)ÇÏ¿´À¸¸ç ¼¼´¢°ü °£Áú ¼¶À¯È­µµ Áõ°¡ÇÏ¿´´Ù.
2. ½ÅÀå Á¶Á÷³» CRP ¾ç¼º ¼¼Æ÷¼ö´Â CsA±ºÀÌ VH±º¿¡ºñÇØ ÇöÀúÈ÷ Áõ°¡ÇÏ¿´À¸³ª CsA+LSRT±º¿¡¼­´Â À¯ÀÇÇÏ°Ô °¨¼ÒÇÏ¿´´Ù(CsA+LSRT 38.0¡¾2.1 vs. CsA 65.0¡¾5.1, p<0.01).
3. OPN mRNA ¹ßÇöÁ¤µµ´Â CsA±ºÀÌ VH±º¿¡ ºñÇØ Áõ°¡ÇÏ¿´À¸³ª CsA+LSRT±º¿¡¼­´Â À¯ÀÇÇÏ°Ô ³·¾Ò´Ù(CsA+LSRT 387.5¡¾46.6% vs. CsA 719.8¡¾58.5%, p<0.05).
4. ED-1 ¾ç¼º ¼¼Æ÷ ¼ö´Â CsA±ºÀÌ VH±º¿¡ ºñÇØ Áõ°¡ÇÏ¿´À¸³ª CsA+LSRT±º¿¡¼­´Â À¯ÀÇÇÏ°Ô ³·¾Ò´Ù(CsA+LSRT 30.5¡¾8.0 vs. CsA 86.0¡¾11.0, p<0.01).

°á·Ð: ¾ÈÁö¿ÀÅٽŠ¥± ¼ö¿ëü ±æÇ×Á¦ÀÎ LSRTÀº CsA·Î ÀÎÇÑ ¿°Áõ¹ÝÀÀÀ» ¾ïÁ¦ÇÏ¿© ½Åµ¶¼ºÀ» °¨¼Ò½ÃÅ°´Â °ÍÀ¸·Î ÀÌÇصȴÙ.

Background: Long-term treatment of immunosuppresant CsA causes interstitial inflammation and fibrosis in the kidney. Renin-angiotensin system (RAS) plays the most important role in the pathogenesis CsA-induced renal injury. Accordingly we evaluated the anti-inflammatory effect of angiotensin II blockades using losartan (LSRT) in a rat model of chronic CsA nephropathy.

Methods: Male Sprague-Dawley rats, initially weighing 225 to 250 g, were used. After 1 week of a low-salt diet (0.05% sodium), the rats were randomized into four groups and treated for 4 weeks. The Vehicle (VH) group was treated with olive oil. The VH+LSRT group was treated with olive oil and LSRT. The CsA group received CsA. The CsA+LSRT group was simultaneously treated with CsA and LSRT. The anti-inflammatory effect of LSRT was evaluated with C-reactive protein (CRP) expression, osteopontin (OPN) mRNA and protein expression, and ED-1 infiltration.

Results: The CsA treatment caused an increase in serum creatinine and a decrease in creatinine clearance compared with that of the VH group. Intrarenal CRP positive cells were significantly decreased in the CsA+LSRT group compared with the CsA group (38.0¡¾2.1 vs. 65.0¡¾5.1, p<0.01). In the CsA group, the degree of OPN mRNA expression was increased compared with that of the VH group. But, OPN mRNA expression was decreased in the CsA+LSRT group (387.5¡¾46.6% vs. 719.8¡¾58.5%, p<0.05). In the degree of ED-1 infiltration, we had a similar results such as CRP and OPN mRNA expression (CsA group 30.5¡¾8.0 vs. CsA+LSRT 86.0¡¾11.0, p<0.01).

Conclusion: We concluded that the anti-inflammatory effects of angiotensin II blockade has a potential protective effect against CsA-induced renal injury.(Korean J Med 67:615-624, 2004)

Å°¿öµå

Cyclosporine nephropathy;Angiotensin II blockade;C-reactive protein; Osteopontin;ED-1

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS